Learn about the symptoms and causes of cervical cancer. Learn about effective diagnosis, treatment methods, and HPV prevention and vaccination options.
Table of Contents
- What is cervical cancer? – Definition and types
- Most common symptoms of cervical cancer – what to look out for?
- Main causes and risk factors for cervical cancer
- Diagnostics in cervical cancer – tests that save lives
- Cervical cancer treatment – methods and innovative therapies
- Prevention and HPV vaccination – how to protect yourself?
What is cervical cancer? – Definition and types
Cervical cancer is a malignant tumor that develops in the cervix—the lower part of the uterus, which connects the organ to the vagina. It is one of the most common cancers of the female reproductive organs worldwide, particularly in developing countries, where prevention and diagnostics are less accessible. The development of cervical cancer is a multi-stage process that can take many years. It starts with precancerous changes, also referred to as dysplastic lesions, which may gradually transform into invasive cancer. The vast majority of cervical cancer cases are linked to chronic infection with the human papillomavirus (HPV). Cells of the cervix, under the influence of oncogenic strains of this virus, can undergo uncontrolled growth and mutations, leading to the development of cancer. It is crucial to understand that cervical cancer does not occur suddenly and often develops without symptoms for a long time, which is why regular Pap smears and HPV tests are essential for early detection of potentially dangerous changes. Modern medicine distinguishes between different types of cervical cancers depending on the cell type from which the tumor arises and its rate of growth.
The most common type of cervical cancer is squamous cell carcinoma (carcinoma planoepitheliale), accounting for about 70–80% of all cases. This cancer originates in the multi-layered squamous epithelium covering the external part of the cervix (the vaginal portion, or portio vaginalis). A characteristic feature of squamous cell carcinoma is its heterogeneity – it can present as a highly differentiated form with lower malignancy, as well as a less differentiated form with aggressive progression and rapid metastasis. The second most frequently occurring type is adenocarcinoma, originating from the glandular cells of the cervical canal. Adenocarcinoma accounts for about 10–20% of cases and is notably harder to detect during standard cytology, as it develops deeper inside the cervical canal. There are also rarer subtypes, such as adenosquamous carcinoma, which shows features of both squamous and glandular cancer, as well as rare undifferentiated, small cell, or neuroendocrine tumors. It is also worth mentioning precancerous changes—known as cervical intraepithelial neoplasia (CIN)—which do not yet mean cancer is present, but are considered potentially threatening conditions requiring further observation or treatment. Cervical cancers differ in clinical presentation, growth rate, metastatic potential, and response to various therapies, so proper diagnosis and typing are essential. Accurate identification allows for effective treatment selection and assessment of future prognosis, minimizing the risk of complications. Reliable knowledge about the types, background, and characteristics of cervical cancer is crucial for women to make informed decisions regarding prevention, screening, and the treatment of cancerous changes in this area.
Most common symptoms of cervical cancer – what to look out for?
In its early stages, cervical cancer may be asymptomatic, causing the disease to be diagnosed only at a more advanced stage. Thus, awareness of the most common symptoms and the ability to recognize them are crucial for women of all ages. The symptoms of cervical cancer are often non-specific and can be confused with complaints accompanying other gynecological conditions. The most characteristic warning sign is abnormal vaginal bleeding—especially intermenstrual bleeding, heavy or prolonged periods, as well as bleeding after sexual intercourse, even from light cervical trauma. In post-menopausal women, any vaginal bleeding requires immediate gynecological consultation, as this phenomenon practically does not occur naturally in this age group. Other early symptoms may include foul-smelling vaginal discharge, copious, sometimes pinkish or bloody in color. Such symptoms are often wrongly attributed to vaginal infections or hormonal disturbances and are therefore easily underestimated, delaying cancer diagnosis. As the disease progresses, there may be pain in the lower abdomen, sacral, and lumbar regions, as well as difficulties urinating or passing stools, indicating local invasion of neighboring tissues. Some women may report a feeling of pelvic pressure, pain during intercourse, or increasing fatigue without a clear cause.
It should be emphasized that symptoms depend on the advancement of the disease and do not always occur simultaneously. In early-stage cancer, the only indication may be changes detected during routine cytology or HPV testing, which highlights the importance of regular preventive checks even in apparently healthy women. As cancer develops, alongside bleeding and discharge, there may also be general symptoms such as chronic fatigue, weight loss, or anemia from persistent blood loss. In very advanced cases, swelling of the lower limbs, problems with urination or stool passage associated with cancer infiltration of nearby organs, and even vesicovaginal or rectovaginal fistulas may occur. The scale and type of symptoms are also influenced by the patient’s age, coexisting conditions, and individual tolerance to the developing cancer process. The symptoms listed, especially when combined with risk factors such as early sexual activity, multiple sexual partners, recurrent HPV infections, or smoking, should prompt urgent gynecological consultation. Quick reaction to early symptoms offers the best chance for complete recovery and allows for the use of less invasive therapeutic methods.
Main causes and risk factors for cervical cancer
The most important cause of cervical cancer development is a chronic infection with the human papillomavirus (HPV), particularly the oncogenic types 16 and 18, which are responsible for nearly 70% of all cases. HPV infection is usually sexually transmitted. Most women come into contact with HPV at some point in their lives, but in some, the infection is not eliminated by the immune system and becomes chronic, leading to precancerous lesions and, consequently, cancer. The risk of persistent infection and cell transformation increases with the addition of other environmental and individual risk factors. Notable among these are early onset of sexual activity (before age 18), a high number of sexual partners, risky sexual behaviors, and the presence of other sexually transmitted diseases. The condition of the immune system is extremely important—immunosuppression, for example due to HIV infection or after transplantation, significantly increases the tendency towards cervical cancer since the body is less able to eliminate HPV and control tumor development.
Other significant risk factors include smoking. Tar and other toxins from cigarettes penetrate the cervical mucus and promote mutation processes, increasing the risk of epithelial cell pathology. Smokers are up to twice as likely to develop cervical cancer as non-smokers. Long-term use of oral hormonal contraceptives, especially for more than five years, as well as multiple pregnancies and births, which can cause micro-injuries to the cervix and facilitate HPV penetration, also matter. Additionally, the risk increases among women who do not undergo regular preventive screenings, making early detection of precancerous changes impossible. Genetic factors may also play a role: studies indicate that the presence of certain gene variants related to immune response (e.g., HLA) can influence susceptibility to persistent HPV infection and cell transformation. Other possible contributors include poor intimate hygiene, deficiencies in vitamins (especially A, C, and folic acid), chronic inflammation of the reproductive tract, and even prolonged stress—all negatively affect the cervical microenvironment and may indirectly contribute to cancer development. Though risk factors often aggregate, this does not mean that every exposed woman will fall ill—individual predisposition and immune effectiveness are key. Advanced forms of cervical cancer more often occur in populations with less access to healthcare, education about prevention, and HPV vaccination, highlighting the importance of coordinated preventative efforts at the societal level.
Diagnostics in cervical cancer – tests that save lives
Early and precise diagnosis of cervical cancer is crucial for successful treatment and the best chance of complete recovery and survival. The diagnostic process is based on several stages, beginning with regular screening tests such as cytology, advanced molecular tests, the identification of cancerous changes, and assessment of their advancement. The most important tool of prevention and early diagnostics is the Pap smear (cervical cytology test). Cytology enables the evaluation of cells lining the cervix and the detection of precancerous lesions (CIN) and early cancer stages. Thanks to cytological screening, the number of cases and deaths from cervical cancer has significantly decreased in developed countries—regular tests allow for detecting abnormalities even when the disease is asymptomatic. In Poland, women aged 25 to 59 are recommended to have cytology every three years, but frequency should be individually tailored—more frequent checks are advised for women at heightened risk, such as those with prior abnormal test results. DNA tests for high-risk human papillomavirus (HPV HR), especially for oncogenic strains, are becoming increasingly important. The HPV test, performed from the same sample as cytology, detects the virus’s presence and assesses the cancer risk before cell changes emerge. In many countries, HPV testing is becoming an equivalent or even preferred screening tool, especially for women over 30. Combining cytological and molecular tests allows for even more effective detection of abnormalities and individualized diagnostic recommendations.
If an abnormal cytology or high-risk HPV infection is detected, the woman should undergo further diagnostic tests targeted at evaluating and characterizing the pathological changes. The primary instrument for in-depth diagnostics is colposcopy – a painless, non-invasive microscopic examination of the cervix, allowing the specialist to identify lesions requiring biopsy for a histopathological examination. Colposcopy allows not only for epithelial assessment but also for planning further management—from liquid-based cytology, through immunocytochemical tests, to precise cervical biopsy. The biopsy is the decisive stage—taken samples are examined microscopically by a pathologist, confirming the presence of cancer cells and determining the histological type, stage, and potential treatment indications. In cases with cancer suspicion, imaging diagnostics may also be necessary—transvaginal ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), and PET, which allow evaluation of the disease’s extent, lymph node involvement, or metastases. Comprehensive diagnostics allow precise staging of the disease with the FIGO system, which is essential for planning treatment—surgery, radiotherapy, chemotherapy, or combined approaches. The use of modern diagnostic methods, including HPV genotyping and molecular testing, also enables identification of women at increased risk of precancer progression, who require intensive observation or treatment. It is important to stress that successful combat against cervical cancer depends not only on access to high-quality diagnostics, but also on health education and regular use of prevention—only then does detecting threatening lesions in the precancerous or early phase offer a chance for a cure and significantly lowers the mortality associated with this cancer.
Cervical cancer treatment – methods and innovative therapies
The treatment of cervical cancer is a complex process, which should be tailored to the stage of the disease, tumor histological type, and the overall health of the patient. The greatest chance for complete recovery is for women diagnosed in the early stage, when lesions are confined to the cervix. Surgical procedures are the standard in such cases and include conization (removal of a cone-shaped piece of the cervix) or simple hysterectomy, that is, removal of the uterus. For women planning to preserve fertility, fertility-sparing treatment is possible, such as trachelectomy (retaining the uterine body while removing the cervix)—a procedure recommended in very early, carefully selected cases. In more advanced stages, when the cancer spreads beyond the cervix or metastasizes to nearby lymph nodes, combined treatment is necessary. Radical hysterectomy with removal of the ovaries and pelvic lymphadenectomy, often supported by radiotherapy and chemotherapy, is the standard here, increasing the effectiveness of local treatment and minimizing the risk of disease recurrence. In some cases, especially when surgery is contraindicated for health reasons, treatment relies primarily on radiotherapy along with cytotoxic drugs (most commonly cisplatin). Radiotherapy is of two types: external beam radiotherapy and brachytherapy (internal irradiation of the tumor), often combined to amplify the therapeutic effect. Optimal selection of treatment methods is based on results of imaging diagnostics, pathomorphological assessments, and the patient’s general condition, with therapeutic decisions made in multidisciplinary teams of gynecologic oncologists, radiation therapists, and medical oncologists.
The development of medicine and new technologies has introduced innovative treatment supplements, especially for those with more advanced or recurrent cancer. Among the most promising advances is immunotherapy, using monoclonal antibodies (e.g. pembrolizumab) that boost the immune response against cancer cells. Immunotherapy, although currently registered primarily for select patient groups with advanced disease or relapse after standard therapy, opens new perspectives for improving survival and quality of life. Targeted therapies are also increasingly used, focusing on blocking key molecular mechanisms of cancer cell development, such as angiogenesis inhibitors (bevacizumab), which limit the formation of new blood vessels nourishing the tumor. A crucial element of modern treatment is personalization based on the tumor’s molecular profile and patient’s health conditions. Minimally invasive methods such as laparoscopic or robotic surgery are also dynamically spreading, allowing precise removal of lesions with fewer complications and faster recovery. Also important is supportive care, including physiotherapy, psychological support, and sexual and urogynecological rehabilitation, all of which strongly influence the quality of life of patients after treatment. Furthermore, in young women with preserved fertility and early-stage cancer, fertility-sparing approaches are increasingly considered, enabling future motherhood. Strict post-treatment monitoring, regular follow-up, and health education are also vital to quickly detect recurrence and implement appropriate therapy as needed.
Prevention and HPV vaccination – how to protect yourself?
Effective prevention of cervical cancer starts with understanding the role of the human papillomavirus (HPV) in the development of the disease and implementing strategies to minimize the risk of infection and complications. The most important element of primary prevention is HPV vaccination, recommended for both girls and boys from age 9, with the optimal age for vaccine administration at 11–13 years—ideally before sexual debut, when the risk of prior exposure is minimal. Available vaccines—bivalent, quadrivalent, and nonavalent—protect against the most important oncogenic HPV types (especially 16 and 18), responsible for about 70% of cervical cancer cases, and those causing other genital cancers and benign lesions such as genital warts. It is worth emphasizing that vaccination is also effective in young adults and recommended in Poland for women and men up to age 26, though research confirms immunization benefits for older individuals, particularly before exposure to new viral types. HPV vaccine programs organized by local and national governments and state funding of vaccination have greatly improved immunological protection accessibility and reduced disease incidence, as seen in countries with long-standing vaccination traditions such as Australia or the UK.
Secondary prevention consists of systematic screening, allowing early detection of precancerous lesions and timely treatment before invasive cancer develops. Regular cytology, HPV testing, and health education significantly lower the number of women dying from cervical cancer. Modifiable risk factors are also important—limiting the number of sexual partners, using condoms, avoiding early sexual initiation, and treating sexually transmitted infections play a real role in lowering the risk of HPV infection. Significant roles are also attributed to intimate hygiene, a healthy lifestyle, fighting addictions (especially smoking), and boosting immunity with a balanced diet and regular exercise. Pregnant women and immunocompromised individuals should receive individually tailored preventive care, while broad-based education should include men as well as women, as key participants in virus transmission. By combining vaccination, regular examinations, and healthy habits, it is possible to significantly minimize the risk of developing cervical cancer or other HPV-related cancers, and to limit the public health burden of long-term infection consequences.
Summary
Cervical cancer is a serious disease that can be effectively prevented and treated thanks to early diagnostics and health awareness. Recognizing the symptoms and main causes, including HPV infection, allows for quick action and reduces the risk of serious consequences. Modern treatment methods, combined with cytological screening and regular prevention, significantly increase chances of recovery. Don’t forget about HPV vaccination—it’s effective protection against cervical cancer. Take care of your health with systematic check-ups and appropriate preventive measures.
